SEC Form 4 · accession 0001209191-18-059146
AGIOS PHARMACEUTICALS, INC. · AGIO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David P Schenkein
Officer — Chief Executive Officer · Director
Period of report
Nov 8, 2018
Accepted (ET)
Nov 19, 2018 · 4:01 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001439222
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common stockF2 | Nov 8, 2018 | G | 1,000 | $0.00 | D | 270,772 | I | See footnote |
| Common stock | holding | — | — | — | 83,849 | D | ||
| Common stockF3 | holding | — | — | — | 79,082 | I | See footnote |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This disposition reflects a gift of 1,000 shares to a charitable trust.
- F2Shares held by David P. Schenkein 2004 Revocable Trust, of which the reporting person is trustee and beneficiary.
- F3Shares held by Amy P. Schenkein 2004 Revocable Trust, of which the reporting person's spouse is trustee and beneficiary.